Triglyceride-Rich Lipoproteins

Maaike Kockx; Leonard Kritharides

doi:10.1016/j.ccl.2017.12.008

Triglyceride-Rich Lipoproteins

Cardiol Clin. 2018 May;36(2):265-275. doi: 10.1016/j.ccl.2017.12.008.

Authors

Maaike Kockx¹, Leonard Kritharides²

Affiliations

¹ Atherosclerosis Laboratory, ANZAC Research Institute, University of Sydney, Concord Repatriation General Hospital, Gate 3 Hospital Road, Concord, New South Wales 2139, Australia.
² Department of Cardiology, Concord Hospital, Atherosclerosis laboratory, ANZAC Research Institute, University of Sydney, 3rd Floor, Hospital Road, Concord, NSW 2139, Australia. Electronic address: leonard.kritharides@sydney.edu.au.

PMID: 29609756
DOI: 10.1016/j.ccl.2017.12.008

Abstract

Plasma triglyceride levels are causally related to an increased risk of cardiovascular disease. Here, the authors summarize their understanding of triglyceride-rich lipoprotein metabolism, previous and newly identified regulators, and their relevance as candidate targets for therapeutic intervention.

Keywords: Angiopoietin-like proteins; Apolipoprotein CIII; Cardiovascular risk; Lipoprotein lipase; Triglyceride-lowering therapy; Triglyceride-rich lipoproteins; Triglycerides.

Publication types

Review

MeSH terms

Cardiovascular Diseases* / blood
Cardiovascular Diseases* / etiology
Cardiovascular Diseases* / prevention & control
Humans
Hypertriglyceridemia* / blood
Hypertriglyceridemia* / complications
Hypertriglyceridemia* / drug therapy
Hypolipidemic Agents / therapeutic use*
Lipid Metabolism / physiology*
Lipoproteins / blood*
Triglycerides / blood*

Substances

Hypolipidemic Agents
Lipoproteins
Triglycerides
lipoprotein triglyceride